Sermorelin
Also known as: GRF(1-29)-NH₂, GHRH(1-29)-NH₂, Sermorelin acetate, Geref
3 notable studies · 3 references
TLDR
Sermorelin is the synthetic 29-amino-acid active fragment of human GHRH that stimulates endogenous pituitary growth-hormone release through the GHRH receptor, with substantial direct human endocrine evidence and historical clinical evidence in children with growth-hormone deficiency, but those findings do not establish the modern anti-aging, body-composition, or performance claims commonly associated with its off-label use.
Research Supports
- Studied for stimulating endogenous growth-hormone release via the GHRH receptor
- Used as a diagnostic provocative test of pituitary GH secretory capacity
- Investigated for treatment of pediatric growth-hormone deficiency
- Examined for interactions with GHRP/ghrelin-receptor secretagogues
Observations Reported in Research
- Increased mean height velocity from about 4.1 cm/year to 7.2 cm/year after 12 months in GH-deficient children (Geref International Study Group, 1996)
- Reliably stimulated pituitary GH release via IV and subcutaneous administration (Prakash & Goa review, 1999)
- Produced distinct GH responses compared with GHRP-2 and combined stimulation in children with GH insufficiency (1995)
These are brief summaries of what the referenced research examined or reported — not conclusions about safety or effectiveness, and not medical advice. See Notable Studies and Sources & References below for the full context and citations.
At a Glance
Classification: Synthetic 29-amino-acid growth hormone-releasing hormone fragment; GHRH receptor agonist; growth-hormone secretagogue
Sermorelin is the first 29 amino acids of human GHRH, prepared as a C-terminal amide. Those first 29 residues retain the biological activity required to stimulate the pituitary GHRH receptor, causing endogenous growth-hormone release. Clinical literature describes sermorelin as the shortest synthetic GHRH analogue retaining full GHRH biological activity. Unlike many compounds in the research-peptide market, sermorelin has genuine human clinical history. It has been studied for: - Growth-hormone stimulation - Diagnosis of GH deficiency - Pediatric idiopathic GH deficiency - Linear growth - Pituitary reserve. A multicenter study treated 110 prepubertal GH-deficient children for up to one year. Among the 86 included in efficacy analysis, mean height velocity increased from approximately 4.1 cm/year at baseline to 7.2 cm/year after 12 months. However, historical clinical evidence for pediatric GH deficiency does not establish the modern claims commonly made around sermorelin for: - Anti-aging - Muscle gain - Fat loss - Athletic recovery - “GH optimization” in otherwise healthy adults. Those are separate questions.
What Is Sermorelin?
Human GHRH is a hypothalamic peptide that signals the anterior pituitary to release growth hormone. The first 29 residues contain the biologically active portion necessary for GHRH-receptor stimulation. Sermorelin is essentially: human GHRH(1-29)-NH₂ rather than a heavily redesigned peptide. That's the first critical distinction from Modified GRF. Sermorelin Native GHRH residues 1–29 Modified GRF (1-29) GHRH residues 1–29 with four substitutions CJC-1295 with DAC Modified GRF-like backbone plus an albumin-binding modification These aren't interchangeable names.
What Are Researchers Studying?
Growth-hormone release
This is sermorelin's best-established effect. Sermorelin stimulates endogenous GH secretion from the anterior pituitary by activating the normal GHRH pathway. Both intravenous and subcutaneous administration have demonstrated GH-releasing activity in humans. This makes sermorelin fundamentally different from administering recombinant GH itself: Sermorelin stimulates pituitary GH release; Somatropin is exogenous growth hormone.
Growth-hormone deficiency diagnosis
Sermorelin historically served as a provocative test of pituitary GH secretion. Administering GHRH(1-29) and measuring the subsequent GH response can provide information about pituitary secretory capacity. There is an important physiological limitation: A patient can have impaired hypothalamic GHRH production while retaining a pituitary capable of responding when externally stimulated. Therefore a normal sermorelin response doesn't necessarily exclude every form of GH-axis dysfunction.
Pediatric growth
Sermorelin has direct human treatment evidence in children with GH deficiency. In a multicenter study, once-daily GHRH(1-29) increased average height velocity substantially during the first treatment year. A broader clinical review concluded that sermorelin produced catch-up growth in many GH-deficient children, although responses varied and evidence concerning final adult height remained incomplete.
GHRH + GHRP interaction
GHRH signaling can interact strongly with ghrelin/GHSR-based secretagogues. In a small human study involving children with GH insufficiency or idiopathic short stature, researchers compared GHRH(1-29), GHRP-2 and their combination. Responses differed according to underlying GH-axis function, illustrating that GHRH-receptor stimulation and GHSR stimulation are biologically distinct but interacting pathways. This explains why Aminodex should keep Sermorelin / CJC / GHRH analogues separate from Ipamorelin / GHRP-2 / GHRP-6 / Hexarelin.
IGF-1 signaling
Sermorelin stimulates endogenous GH, which can subsequently increase hepatic and peripheral IGF-1 signaling. The sequence is approximately: Sermorelin → GHRH receptor → pituitary GH secretion → GH receptor signaling → IGF-1 production. Therefore IGF-1 effects are primarily downstream consequences of GH-axis stimulation, rather than direct IGF-1-receptor agonism.
Healthy-adult aging/body composition
This is where modern marketing runs ahead of the evidence. Historical sermorelin research established: GH release, diagnostic utility, pediatric growth effects. That doesn't automatically establish meaningful benefits for healthy adults seeking: Increased muscle, Reduced body fat, Faster recovery, Better sleep, Increased energy, Slower aging. The older clinical literature does not justify treating those outcomes as established sermorelin effects.
How Does It Work?
This mechanism is unusually well established: Sermorelin / GHRH(1-29) → GHRH receptor on anterior-pituitary somatotrophs → intracellular signaling → endogenous GH secretion → GH-receptor activity in peripheral tissues → increased downstream IGF-1 signaling and other GH-dependent effects. Unlike some of our bioregulator profiles, we don't need to invoke speculative DNA binding to explain sermorelin. It acts through a known physiological hormone receptor pathway.
What Does the Research Show?
Human research
SUBSTANTIAL for GH stimulation. MODERATE historical evidence for selected pediatric GH-deficiency applications. MUCH WEAKER for modern healthy-adult anti-aging/body-composition claims. That's the right Aminodex distinction. Sermorelin has far stronger direct human evidence than: - Ipamorelin - Modified GRF (1-29) - many research-market GH secretagogues. But evidence should remain indication-specific.
Animal research
Extensive GHRH biology exists across animal models, but human evidence is strong enough that Aminodex doesn't need to lean heavily on animal studies to establish sermorelin's basic GH-releasing activity.
In-vitro research
Extensive mechanistic work supports GHRH-receptor biology. Again, the clinically interesting distinction here is that the principal pharmacodynamic effect has already been demonstrated directly in humans.
Notable Studies
Once Daily Subcutaneous Growth Hormone-Releasing Hormone Therapy Accelerates Growth in Growth Hormone-Deficient Children During the First Year of Therapy
humanOne hundred ten previously untreated prepubertal children with GH deficiency received daily GHRH(1-29) for up to one year. Among 86 children eligible for efficacy analysis, mean height velocity increased from approximately 4.1 cm/year before treatment to 8.0 cm/year at six months and 7.2 cm/year at twelve months. Treatment was generally well tolerated. Limitations: Open-label rather than placebo-controlled; pediatric GH-deficiency population; doesn't establish efficacy for healthy adults, anti-aging, body composition or athletic recovery.
Limitations: Open-label rather than placebo-controlled; pediatric GH-deficiency population; doesn't establish efficacy for healthy adults, anti-aging, body composition or athletic recovery.
View publication →Sermorelin: A Review of Its Use in the Diagnosis and Treatment of Children with Idiopathic Growth Hormone Deficiency
humanThe review evaluated sermorelin as both a diagnostic GH-provocation agent and treatment for pediatric GH deficiency. It concluded that IV and subcutaneous sermorelin reliably stimulate pituitary GH release and that limited treatment data showed increased growth velocity in some prepubertal children.
Limitations: Review rather than a single randomized trial; much of the underlying therapeutic literature is older and pediatric; final adult-height evidence was incomplete.
View publication →Growth Hormone-Releasing Effects of Synthetic Peptide GHRP-2 and Growth Hormone-Releasing Hormone (1-29NH₂) in Children with GH Insufficiency and Idiopathic Short Stature
humanResearchers compared GHRH(1-29), GHRP-2 and combined stimulation in children with GH insufficiency or idiopathic short stature. The experiment demonstrated distinct responses to the two secretagogue pathways and illustrated their interaction.
Limitations: Only 15 children; acute endocrine-response study rather than long-term treatment trial.
View publication →What We Still Don't Know
- Modern comparative efficacy versus current GH therapies - Final adult-height effects from historical pediatric treatment - Long-term outcomes in contemporary populations - Clinical benefit in otherwise healthy adults - Whether modest GH/IGF-1 changes improve meaningful aging outcomes - Whether it meaningfully improves healthy-adult body composition - Whether it improves recovery or sleep independently of underlying GH deficiency - Long-term risk-benefit for off-label healthy-adult use.
Related Compounds
Recent publications
Latest titles from PubMed, not reviewed by Aminodex. Not an endorsement. See all on PubMed ↗
Take the Sermorelin research with you.
Get the Aminodex Sermorelin Brief—a concise summary of the research, notable studies, evidence types, limitations, and references.
One-time email. We do not add you to any mailing list.
Sources & References
- Prakash A, Goa KL. Sermorelin: a review of its use in the diagnosis and treatment of children with idiopathic growth hormone deficiency. BioDrugs. 1999.
- Geref International Study Group. Once daily subcutaneous growth hormone-releasing hormone therapy accelerates growth in growth hormone-deficient children during the first year of therapy.
- Growth hormone-releasing effects of GHRP-2 and GHRH(1-29NH₂) in children with GH insufficiency and idiopathic short stature.
Supplier Listings
A directory of relevant research suppliers for this compound is not yet available.